Last reviewed 2026-04-20 · How we verify

Liserdol (METERGOLINE)

Phase 2 active Small molecule

Liserdol (generic name: METERGOLINE) is a metergoline drug. It is currently in Phase 2 development.

Liserdol works by binding to serotonin receptors in the brain, specifically the 5-hydroxytryptamine receptor 2C.

Liserdol, also known as METERGOLINE, is a small molecule drug that targets the 5-hydroxytryptamine receptor 2C. It belongs to the metergoline class and works by interacting with serotonin receptors in the brain. However, due to the lack of FDA approval information, its approved indications and commercial status are unknown. Liserdol has a short half-life of 0.93 hours and limited bioavailability of 23%. Further research is needed to determine its safety and efficacy.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	METERGOLINE
Drug class	metergoline
Target	5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your brain is like a busy city with many different signals being sent and received. Serotonin is a chemical messenger that helps regulate mood, appetite, and other functions. Liserdol helps calm down the serotonin signals by blocking the 5-hydroxytryptamine receptor 2C, which can help reduce symptoms of certain conditions.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Liserdol CI brief — competitive landscape report
Liserdol updates RSS · CI watch RSS

Frequently asked questions about Liserdol

What is Liserdol?

Liserdol (METERGOLINE) is a metergoline drug.

How does Liserdol work?

Liserdol works by binding to serotonin receptors in the brain, specifically the 5-hydroxytryptamine receptor 2C.

What is the generic name of Liserdol?

METERGOLINE is the generic (nonproprietary) name of Liserdol.

What drug class is Liserdol in?

Liserdol belongs to the metergoline class. See all metergoline drugs at /class/metergoline.

What development phase is Liserdol in?

Liserdol is in Phase 2.

What does Liserdol target?

Liserdol targets 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6 and is a metergoline.

Drug class: All metergoline drugs
Target: All drugs targeting 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing